Table 1.
IC50 for inhibition toward EGFR activity and the growth of human carcinoma cell lines of complexes 1–4.
| Compound | IC50 to EGFR (nM)a | IC50 (μM) to cell lines exposed to tested compounds for 48 h | |||||
|---|---|---|---|---|---|---|---|
| A549 | A549/DDP | RFd | A431 | MCF-7 | HeLa | ||
| 1 | 9.2 ± 0.6 | 13.2 ± 1.8 | 28.9 ± 1.7 | 2.2 | 7.7 ± 1.8 | 20.3 ± 2.7 | 29.8 ± 5.0 |
| 2 | 7.0 ± 3.0 | 6.5 ± 2.5 | 13.5 ± 1.8 | 2.1 | 1.4 ± 0.4 | 27.7 ± 2.2 | 19.4 ± 5.6 |
| 3 | 10.9 ± 3.0 | 12.2 ± 2.2 | 32.0 ± 1.6 | 2.6 | 7.4 ± 0.4 | 24.8 ± 1.1 | 13.4 ± 1.3 |
| 4 | 9.6 ± 2.5 | 11.6 ± 1.1 | 26.6 ± 3.0 | 2.3 | 7.9 ± 3.2 | 19.9 ± 2.7 | 39.4 ± 0.1 |
| Gefitinib | 94.0 ± 3.1b | 16.0 ± 1.0 | 24.9 ± 1.2 | 1.6 | 12.6 ± 1.3 | 19.9 ± 2.0 | 30.8 ± 3.0 |
| Cisplatin | NTc | 10.1 ± 1.6 | 30.9 ± 1.1 | 3.1 | 11.1 ± 0.4 | 15.6 ± 0.8 | 12.9 ± 0.6 |
Gefitinib and cisplatin were used as positive controls.
a
The IC50 data against EGFR were determined by ELISA in the presence of 200 μM of ATP.
b
These data are adapted from Du et al. (2016).
c
Not tested.
d
RF (resistance factor) = IC50 (A549/DDP)/IC50 (A549).